Neuberg Diagnostics to invest Rs 300 cr for expansion

Mumbai: Neuberg Diagnostics, an alliance of five leading pathology laboratories from India, South Africa and the UAE, is planning to invest Rs 300 crore in India, the Middle East and Africa as part of its expansion plans.

“We are looking at investing another Rs 300 crore for expansion plans in the coming years, which will be funded through internal accruals,” Neuberg Diagnostics chairman GSK Velu told here.

The company having focus on new generation technologies in the diagnostics space, according to Velu has already invested Rs 450 crore in acquiring laboratories in India and abroad and upgrading them.

Neuberg at present has 50 labs and 500 centres in the south and west India, and plans to increase the total count to 150 labs and 1,000 centres in the next three years.

“We will have three world class global reference laboratories located in Bengaluru, Ahmedabad, and Durban (South Africa) carrying out advanced range of testing using new generation in vitro diagnostics techniques,” he said.

The company sees faster growth in African markets and plans to enter into Kenya, Uganda, Nigeria, Tanzania and Ethiopian markets.

According to Velu, new generation technologies like genomics, metabolomics and proteomics that provide accurate diagnosis and also combination diagnostics, where hospitals, pharma companies and pathologists work together, is the future of the diagnostics industry.

“India is lagging behind in terms of technology and we wants to focus in those areas,” he said.

An alliance of five top laboratories like Anand Diagnostic Laboratory, Supratech Micropath, Ehrlich lab, Global labs and Minerva Labs, the company plans to have three infrastructure models global centre of excellence, regional reference centres and satellite centres.

It also wants to establish research centres in the US and European markets, to get access to latest technologies and bring it to India, according to Velu.

“Talks are on with some universities and small labs in the regions,” he said.

The company, which is growing at a compounded annual growth rate of 15 per cent, clocked an consolidated revenue of Rs 400 crore last year and hopes to cross Rs 1,000-crore mark by 2021-22.

  • Related Posts

    Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

    Bharat Mandapam witnessed Spectacle of Crazy Innovations by Maker of Ssi Mantra, Best in class Surgical Robot New Delhi: It was a veritable display of innovative potential and prowess of…

    On World Health Day ‘CAHO Na Patient Se Pyaar Hai’

    Chennai hosts 3 Day International Conference CAHOCON on Patient Safety in Hospitals starting April 10 New Delhi:  Patient safety in hospitals is a global concern, more so in India. It…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    IPC releases draft NFI-2026 to promote rational use of medicines

    IPC releases draft NFI-2026 to promote rational use of medicines

    Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

    Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

    US market to dent India pharma earnings even as domestic growth remains firm

    US market to dent India pharma earnings even as domestic growth remains firm

    Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg

    Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg